{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:42Z","timestamp":1793726022511,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T00:00:00Z","timestamp":1700352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T00:00:00Z","timestamp":1700352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82001740"],"award-info":[{"award-number":["No. 82001740"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["No. 202203021221269"],"award-info":[{"award-number":["No. 202203021221269"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40744-023-00620-7","type":"journal-article","created":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T14:02:26Z","timestamp":1700402546000},"page":"79-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy, Safety and the Lymphocyte Subset Changes of Low-Dose IL-2 in Patients with Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"11","author":[{"given":"Qinyi","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiexiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cairui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuechun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1341-7588","authenticated-orcid":false,"given":"Sheng-Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,19]]},"reference":[{"issue":"11","key":"620_CR1","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","volume":"78","author":"S Safiri","year":"2019","unstructured":"Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990\u20132017: a systematic analysis of the global burden of disease study 2017. Ann Rheum Dis. 2019;78(11):1463\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"620_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","volume":"21","author":"GC Tsokos","year":"2020","unstructured":"Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605\u201314.","journal-title":"Nat Immunol"},{"key":"620_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109031","volume":"239","author":"K Tenbrock","year":"2022","unstructured":"Tenbrock K, Rauen T. T cell dysregulation in SLE. Clin Immunol. 2022;239: 109031.","journal-title":"Clin Immunol"},{"issue":"7","key":"620_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jcp.56.7.481","volume":"56","author":"CC Mok","year":"2003","unstructured":"Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481\u201390.","journal-title":"J Clin Pathol"},{"issue":"5","key":"620_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00296-008-0809-z","volume":"29","author":"YJ Xiang","year":"2009","unstructured":"Xiang YJ, Dai SM. Prevalence of rheumatic diseases and disability in China. Rheumatol Int. 2009;29(5):481\u201390.","journal-title":"Rheumatol Int"},{"key":"620_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.741938","volume":"12","author":"JS Shin","year":"2021","unstructured":"Shin JS, Kim I, Moon JS, et al. Intranuclear delivery of HIF-1\u03b1-TMD alleviates EAE via functional conversion of TH17 cells. Front Immunol. 2021;12: 741938.","journal-title":"Front Immunol"},{"key":"620_CR7","doi-asserted-by":"crossref","unstructured":"Fasching P, Stradner M, Graninger W, et al. Therapeutic Potential of Targeting the Th17\/Treg Axis in Autoimmune Disorders. Molecules 2017;22(1).","DOI":"10.3390\/molecules22010134"},{"issue":"5","key":"620_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","volume":"15","author":"D Klatzmann","year":"2015","unstructured":"Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283\u201394.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"620_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.molmed.2022.04.010","volume":"28","author":"Y Yuan","year":"2022","unstructured":"Yuan Y, Kolios AGA, Liu Y, et al. Therapeutic potential of interleukin-2 in autoimmune diseases. Trends Mol Med. 2022;28(7):596\u2013612.","journal-title":"Trends Mol Med"},{"key":"620_CR10","doi-asserted-by":"crossref","unstructured":"Zhang SX, Wang J, Wang CH, et al. Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2021;13:1759720x211011370.","DOI":"10.21203\/rs.3.rs-93717\/v1"},{"key":"620_CR11","first-page":"942","volume":"77","author":"X Jia","year":"2018","unstructured":"Jia X, An H, Fan K, Li F, Li X. Absolute number of peripheral CD4-CD25+FOXP3+T cells decreases and restores after low-dose interleukin-2 treatment in rheumatoid arthritis. Ann Rheum Dis. 2018;77:942\u2013942.","journal-title":"Ann Rheum Dis"},{"key":"620_CR12","unstructured":"Mang SX, Miao M, Liu XQ, Ma XW, Wu XY, Li XF. The Efficacy and Safety of Low Dose IL-2 Therapy in over-Treated Patients with Rheumatoid Arthritis: A Preliminary Study. Arthritis & Rheumatology 2016;68."},{"key":"620_CR13","unstructured":"Jia X, An H, Fan K, Li F, Li X, Study on absolute number of peripheral CD8 + CD25 + Foxp3 + T cells in patients with rheumatoid arthritis and effect of low-dose interleukin-2 on it. International J Rheumatic Dis 2018. 21: 98\u201399."},{"issue":"10","key":"620_CR14","first-page":"1310","volume":"32","author":"J Wang","year":"2019","unstructured":"Wang J, Sun HH, Qiao J, et al. Effect and clinical efficacy of low dose IL-2 on regulatory T cells in active rheumatoid arthritis. Chin Clin Res. 2019;32(10):1310\u20134.","journal-title":"Chin Clin Res"},{"key":"620_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.947341","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Zhang SX, Chang JS, et al. Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: a randomized controlled trial. Front Immunol. 2022;13: 947341.","journal-title":"Front Immunol"},{"key":"620_CR16","unstructured":"Yan, M. Low-Dose IL-2 Restored Reduced Regulatory T Cells in Patients with Rheumatoid Arthritis. Arthritis & Rheumatology, 2018. 70."},{"issue":"1","key":"620_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"620_CR18","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He J, Zhang X, Wei Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991\u20133.","journal-title":"Nat Med"},{"issue":"2","key":"620_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1089\/jir.2018.0016","volume":"39","author":"M Shao","year":"2019","unstructured":"Shao M, He J, Zhang R, et al. Interleukin-2 deficiency associated with renal impairment in systemic lupus erythematosus. J Interferon Cytokine Res. 2019;39(2):117\u201324.","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"620_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12865-019-0305-0","volume":"20","author":"C Zhao","year":"2019","unstructured":"Zhao C, Chu Y, Liang Z, et al. Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17\/Treg cells in refractory SLE patients. BMC Immunol. 2019;20(1):32.","journal-title":"BMC Immunol"},{"key":"620_CR21","first-page":"A35","volume":"6","author":"SX Zhang","year":"2019","unstructured":"Zhang SX, Wang J, Wang CH, et al. Low-dose il-2 therapy rescues decreased peripheral lymphocytes in SLE patients with different infectious status. Lupus Sci Med. 2019;6:A35\u20136.","journal-title":"Lupus Sci Med"},{"key":"620_CR22","unstructured":"Jing Wang, Effect of IL-2 on Th17 and Treg cells in patients with systemic lupus erythematosus. 2017, Shanxi Medical University."},{"issue":"6","key":"620_CR23","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1080\/03007995.2022.2065145","volume":"38","author":"JQ Zhang","year":"2022","unstructured":"Zhang JQ, Zhang SX, Wang J, et al. Low-dose IL-2 therapy limits the reduction in absolute numbers of peripheral lymphocytes in systemic lupus erythematosus patients with infection. Curr Med Res Opin. 2022;38(6):1037\u201344.","journal-title":"Curr Med Res Opin"},{"key":"620_CR24","unstructured":"Kai Fan, Expression of CD4~+Treg and CD8~+Treg cells in peripheral blood of patients with systemic lupus erythematosus and effect of low dose of IL-2 on their levels. 2018, Shanxi Medical University."},{"issue":"12","key":"620_CR25","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard-2022-222501","volume":"81","author":"JY Humrich","year":"2022","unstructured":"Humrich JY, et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis. 2022;81(12):1685\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"620_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41392-023-01350-6","volume":"8","author":"H Zhou","year":"2023","unstructured":"Zhou H, et al. Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE. Signal Transduct Target Ther. 2023;8(1):141.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"620_CR27","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","volume":"77","author":"M Miao","year":"2018","unstructured":"Miao M, Hao Z, Guo Y, et al. Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis. 2018;77(12):1838\u201340.","journal-title":"Ann Rheum Dis"},{"key":"620_CR28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/annrheumdis-2016-209632","volume":"76","author":"M Miao","year":"2017","unstructured":"Miao M, Hao Z, Guo Y, et al. The number of treg cells in peripheral blood in pss patients is decreased and low dose IL-2 can promote its proliferation. Ann Rheum Dis. 2017;76:869\u2013869.","journal-title":"Ann Rheum Dis"},{"key":"620_CR29","doi-asserted-by":"publisher","first-page":"204062232091601","DOI":"10.1177\/2040622320916014","volume":"11","author":"J Wang","year":"2020","unstructured":"Wang J, Zhang SX, Hao YF, et al. The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2. Ther Adv Chronic Dis. 2020;11:2040622320916014.","journal-title":"Ther Adv Chronic Dis"},{"key":"620_CR30","first-page":"1267","volume":"78","author":"SX Zhang","year":"2019","unstructured":"Zhang SX, Hao YF, Wang J, Sun HH, Xiao-Feng LI. Imbalance of TH17 and regulatory T cells in patients with psoriatic arthritis and rebalance by low-dose IL-2. Ann Rheum Dis. 2019;78:1267\u20138.","journal-title":"Ann Rheum Dis"},{"key":"620_CR31","doi-asserted-by":"crossref","unstructured":"Qiao Z et al. Low-dose Interleukin-2 for psoriasis therapy based on the regulation of Th17\/Treg cell balance in peripheral blood. Inflammation, 2023.","DOI":"10.21203\/rs.3.rs-2528508\/v1"},{"key":"620_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105912","volume":"77","author":"M Feng","year":"2019","unstructured":"Feng M, Guo H, Zhang C, et al. Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis. Int Immunopharmacol. 2019;77: 105912.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"620_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103186","volume":"21","author":"X Zheng","year":"2022","unstructured":"Zheng X, et al. Low-dose IL-2 therapy restores imbalance between Th17 and regulatory T cells in patients with the dermatomyositis combined with EBV\/CMV viremia. Autoimmun Rev. 2022;21(11): 103186.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"620_CR34","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40744-021-00301-3","volume":"8","author":"M Miao","year":"2021","unstructured":"Miao M, Li Y, Huang B, et al. Treatment of active idiopathic inflammatory myopathies by low-dose interleukin-2: a prospective cohort pilot study. Rheumatol Ther. 2021;8(2):835\u201347.","journal-title":"Rheumatol Ther"},{"key":"620_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.757099","volume":"12","author":"Y Zhufeng","year":"2022","unstructured":"Zhufeng Y, Xu J, Miao M, et al. Modification of intestinal microbiota dysbiosis by low-dose interleukin-2 in dermatomyositis: a post hoc analysis from a clinical trial study. Front Cell Infect Microbiol. 2022;12: 757099.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"620_CR36","doi-asserted-by":"publisher","first-page":"746","DOI":"10.55563\/clinexprheumatol\/lnn76t","volume":"39","author":"X Liu","year":"2021","unstructured":"Liu X, Li W, Liu X, Luo J, Gao C, Li X. Low-dose IL-2 effectively restored decreased regulatory T cells in patients with Beh\u00e7et\u2019s disease. Clin Exp Rheumatol. 2021;39(4):746\u201352.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"620_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103156","volume":"21","author":"R Wu","year":"2022","unstructured":"Wu R, Mu Y, Zhao X, et al. Short-term and low-dose IL-2 therapy increases the reduced Treg cells in patients with microscopic polyangiitis. Autoimmun Rev. 2022;21(9): 103156.","journal-title":"Autoimmun Rev"},{"key":"620_CR38","doi-asserted-by":"crossref","unstructured":"R Wu, R Su, T Ding, H Xue, C Wang. Low-Dose IL-2 restores treg-mediated immune tolerance in patients with anca-associated vasculitis. Ann Rheumatic Dis, 2020. 79: 1079\u20131080.","DOI":"10.1136\/annrheumdis-2020-eular.4346"},{"issue":"12","key":"620_CR39","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1111\/ced.15345","volume":"47","author":"Z Yu","year":"2022","unstructured":"Yu Z, Cheng H, Ding T, et al. Absolute decrease in regulatory T cells and low-dose interleukin-2 therapy: restoring and expanding regulatory T cells to treat systemic sclerosis: a 24-week study. Clin Exp Dermatol. 2022;47(12):2188\u201395.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"620_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12865-019-0305-0","volume":"20","author":"C Zhao","year":"2019","unstructured":"Zhao C, Chu Y, Liang Z, Zhang B, Wang X, Jing X, et al. Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17\/Treg cells in refractory SLE patients. BMC Immunol. 2019;20(1):32.","journal-title":"BMC Immunol"},{"key":"620_CR41","unstructured":"Tingting D. Low dose IL-2 combined with TNF- \u03b1 Clinical efficacy and immunomodulatory effects of inhibitors in the treatment of rheumatoid arthritis, Shanxi Medical University (2022)"},{"key":"620_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.648408","volume":"12","author":"H Gra\u00dfhoff","year":"2021","unstructured":"Gra\u00dfhoff H, Comd\u00fchr S, Monne LR, et al. Low-dose IL-2 therapy in autoimmune and rheumatic diseases. Front Immunol. 2021;12: 648408.","journal-title":"Front Immunol"},{"issue":"13","key":"620_CR43","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.4103\/0366-6999.235114","volume":"131","author":"M Shao","year":"2018","unstructured":"Shao M, Sun XL, Sun H, et al. Clinical relevance of autoantibodies against interleukin-2 in patients with systemic lupus erythematosus. Chin Med J (Engl). 2018;131(13):1520\u20136.","journal-title":"Chin Med J (Engl)"},{"issue":"10","key":"620_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102645","volume":"19","author":"R Wu","year":"2020","unstructured":"Wu R, Li N, Zhao X, et al. Low-dose Interleukin-2: Biology and therapeutic prospects in rheumatoid arthritis. Autoimmun Rev. 2020;19(10): 102645.","journal-title":"Autoimmun Rev"},{"key":"620_CR45","doi-asserted-by":"crossref","unstructured":"Pol JG, Caudana P, Paillet J, Piaggio E, Kroemer G. Effects of interleukin-2 in immunostimulation and immunosuppression. J Exp Med 2020;217(1).","DOI":"10.1084\/jem.20191247"},{"key":"620_CR46","unstructured":"Harris F, Berdugo YA, Tree T. IL-2-based approaches to Treg enhancement. Clin Exp"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00620-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00620-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00620-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T15:31:40Z","timestamp":1705591900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00620-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,19]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["620"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00620-7","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,19]]},"assertion":[{"value":"23 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Qinyi Su, Xinmiao Wang, Yongzhi Li, Jiexiang Zhang, Cairui Bai, Xuechun Wang, Liu Yang, Jingting Zhang, Sheng-Xiao Zhang have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on a secondary analysis of previously conducted and published studies and does not contain any data on human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}